Most people think of GLP-1 medications like Ozempic and Wegovy as weight loss drugs. That's true, but it's only part of the picture. Some of the most exciting research on these medications has nothing to do with the scale — it's about what they do for your heart.
Large clinical trials now show that GLP-1 receptor agonists cut the risk of heart attacks, strokes, and cardiovascular death. And the benefits go beyond just losing weight.
The SELECT Trial: A Landmark Moment
The biggest piece of evidence comes from the SELECT trial, published in 2023. Researchers enrolled over 17,600 adults who had overweight or obesity plus established cardiovascular disease — but no diabetes. Half got semaglutide 2.4 mg (the Wegovy dose), half got a placebo, and the study ran for up to five years.
The results were striking:
- 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death)
- Benefits showed up as early as 8 months into treatment
- It didn't matter what patients weighed at the start — lighter and heavier patients both benefited
- Systemic inflammation markers like C-reactive protein dropped by 37%
This was a big deal. The FDA went on to approve Wegovy specifically for cardiovascular risk reduction — making it the first anti-obesity medication to ever receive that indication.
How GLP-1 Medications Protect the Heart
Researchers think GLP-1 drugs help the cardiovascular system through several pathways, not just by helping people lose weight:
Reducing inflammation. Chronic low-grade inflammation fuels atherosclerosis — the slow buildup of plaque inside your arteries. GLP-1 receptor agonists bring down inflammatory markers like CRP, IL-6, and TNF-alpha. This anti-inflammatory effect appears to come from the drug acting directly on immune cells, not just as a side effect of shedding pounds.
Lowering blood pressure. Patients on GLP-1 medications typically see systolic blood pressure drop by 3-6 mmHg. That sounds modest, but sustained over years, that kind of reduction translates into real cardiovascular protection.
Improving lipid profiles. These drugs tend to bring triglycerides and LDL cholesterol down while nudging HDL cholesterol up. All of that chips away at atherosclerotic risk.
Reducing arterial stiffness. Early data suggests GLP-1 agonists may directly improve endothelial function and make arteries more flexible — both signs of healthier blood vessels.
Weight loss itself. The 15-21% body weight reduction seen with drugs like Wegovy HD absolutely helps the heart too. Excess fat, especially visceral fat packed around organs, is a strong independent risk factor for heart disease.
What About Tirzepatide?
SELECT studied semaglutide specifically. Eli Lilly is running its own large cardiovascular outcomes trial for tirzepatide (Mounjaro/Zepbound) called SURPASS-CVOT. Early signals point toward similar heart benefits, though full results won't land until later in 2026.
Since tirzepatide produces even more weight loss than semaglutide in head-to-head studies, most cardiologists expect the cardiovascular payoff to be at least as strong.
Who Benefits Most?
Based on the evidence so far, cardiovascular benefits are clearest in:
- Adults with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
- Adults with overweight or obesity who carry multiple cardiovascular risk factors
- People with metabolic syndrome (central obesity, high blood pressure, high triglycerides, insulin resistance)
If you have heart disease or stacked cardiovascular risk factors, this is worth bringing up with your doctor. STAT News covers the latest cardiovascular research on GLP-1 medications if you want to stay current. A weight loss clinic that understands these heart-related benefits can help you figure out whether GLP-1 treatment makes sense as part of a broader risk-reduction plan. Our guide to finding the right clinic is a good starting point.
Important Caveats
GLP-1 medications are powerful, but they're not a replacement for the basics. Regular exercise, good nutrition, not smoking, and keeping blood pressure and cholesterol in check all still matter. These drugs work best as one piece of a bigger plan — not as the whole plan.
The side effects are mostly GI-related and manageable for most people, but patients with a history of pancreatitis, medullary thyroid cancer, or MEN2 syndrome should not take these medications.
Talk to a Specialist
If you're interested in GLP-1 treatment with cardiovascular risk reduction in mind, look for a provider who understands both obesity medicine and heart health. More and more weight loss clinics now screen for cardiovascular risk during their intake process.
Search our directory to find clinics offering GLP-1 programs. Browse providers in Houston, Miami, Atlanta, and San Diego.